Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Clopidogrel (Farmak) vs Plavix in healthy volunteers
NCT05125549Phase 1Completed
- Sponsor
- Farmak
- Start
- Jul 2018
- Primary completion
- Aug 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of clopidogrel in atherothrombosis (2 arms), sponsored by Farmak. Primary endpoints: Maximum Plasma Concentration and Area Under the Curve to the last quantifiable concentration. Started Jul 2018; status: completed.
02
Drugs
clopidogrel
03
Conditions
atherothrombosis
Beyond the preview
Go deeper on NCT05125549.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05125549.